New app aims to simplify insulin dosing for diabetes patients
NCT ID NCT06529705
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a mobile app called EkiYou V2 that helps people with diabetes figure out how much insulin to take. 21 adults who use multiple daily insulin injections used the app for 6 weeks. The goal was to see if the app safely improves blood sugar control and makes insulin dosing easier.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EkiYou V2 mobile application
- What this could lead to
- If successful, this app could help people with diabetes better manage their insulin doses and improve blood sugar control without needing extra medication.
- What could go wrong
- This is a very small, early study with only 21 participants and no comparison group. The results may not apply to everyone, and the app might not work as well in real-world, long-term use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
21 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria : * Be over 18 years old; * Have type 1, type 2, or pancreatogenic diabetes; * Have been treated with multiple daily injections of insulin in a basal/bolus regimen for at least 6 months; * Be using a continuous glucose monitoring device such as Dexcom G6, Dexcom One or Freestyle Libre for at least 2 weeks; * Have a time in the glycemic target range (70-180 mg/dl) of less than 70%; * Require at least 15 units of insulin therapy per day; * Use a rapid-acting insulin compatible with the device, such as Novorapid, Humalog, Apidra, Asparte, Sanofi, Fiasp, or Lyumjev; * Use a long-acting insulin compatible with the device, such as Lantus, Abasaglar, Toujeo, Levemir, or Tresiba; * Be able to read and use a smartphone; * Have no visual impairment requiring a specific font for smartphones; * Have basic knowledge of smartphone use; * Indicate their willingness to follow the protocol and sign a written informed consent Exclusion Criteria: * Ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within 6 months prior to inclusion; * Treatment with any hypoglycemia-inducing agent other than insulin (including sulfonylureas and SGLT-2 inhibitors); * Daily insulin requirement exceeding 200 U/day; * Suffering from gastroparesis; * Pancreatopathy secondary to chronic alcoholism; * Known medical condition that, in the investigator's opinion, may interfere with the protocol; * Participation in another clinical trial or administration of an unapproved medication within 4 weeks prior to screening; * Not affiliated with a social security system; * Vulnerable subject: minors, or adults under protection as defined by the Public Health Code, pregnant or breastfeeding women, subjects under guardianship or deprived of liberty; * Person under legal protection; * Person participating in another study with an ongoing exclusion period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes type 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire de Montpellier
Montpellier, France, 34000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which insulin dosing method keeps hospital blood sugar in check?
- Digital dashboard aims to transform diabetes care for kids
- Eye scans could spot Diabetes-Related vision damage years early
- New study aims to measure fear of hypoglycemia in french kids with diabetes
- 12,000 diabetes patients to test remote monitoring system
- Paramedics at your door: new program fights dangerous low blood sugar